Te­va boots its R&D chief; Iron­wood grows the C-suite and In­ter­cept taps new EVP of re­search

Michael Hay­den

→ In the first ma­jor C-suite over­haul un­der new CEO Kåre Schultz, trou­bled Te­va is part­ing ways with R&D chief Michael Hay­den, Glob­al Spe­cial­ty Med­i­cines head Rob Ko­re­mans, and Glob­al Gener­ic Med­i­cines Group leader Di­pankar Bhat­tachar­jee by the end of the year. A num­ber of staffers are be­ing pro­mot­ed to fill the va­can­cies, in­clud­ing Michael Mc­Clel­lan, who will be­come CFO, and Hafrun Fridriks­dot­tir, the new EVP of glob­al R&D.

Gi­na Con­syl­man

→ Cam­bridge, MA-based Iron­wood Phar­ma­ceu­ti­cals $IR­WD — the de­vel­op­er of Linzess and Zu­rampic — has just grown its C-suite by two mem­bers. William Huyett is the new chief op­er­a­tion of­fi­cer, while Gi­na Con­syl­man has been pro­mot­ed to CFO and SVP, of­fi­cial­ly tak­ing a po­si­tion that she has oc­cu­pied since Tom Graney left for Ver­tex. Hav­ing con­sult­ed life sci­ence com­pa­nies at McK­in­sey, where he worked for 30 years, Huyett’s list of re­spon­si­bil­i­ties in­cludes fi­nance, cor­po­rate strat­e­gy, de­vel­op­ment, glob­al op­er­a­tions, in­vestor re­la­tions and cor­po­rate com­mu­ni­ca­tions func­tions. Mean­while Con­syl­man, a Bio­gen vet, will build up­on the work that she has done for Iron­wood since join­ing in 2014.

Joseph Kel­ly, a long­time No­vo Nordisk sales ex­ec­u­tive, is jump­ing ship to run sales and mar­ket­ing at Ra­dius Health, re­plac­ing out­go­ing chief com­mer­cial of­fi­cer David Snow. Join­ing him on the SVP rank is Aman­da Mott, who will take charge of mar­ket ac­cess. These lead­er­ship changes come not long af­ter the sur­prise ap­point­ment of Jes­per Høi­land, al­so a No­vo Nordisk vet, who was re­cruit­ed specif­i­cal­ly to steer Ra­dius’ $RDUS launch of its de­but drug, Tym­los, for os­teo­poro­sis.

Megan Schoeps is re­sign­ing from her po­si­tion as Bellerophon’s con­troller and prin­ci­pal fi­nan­cial of­fi­cer to pur­sue oth­er ca­reer in­ter­ests. The SEC fil­ing notes that she will stay in her role while the com­pa­ny $BLPH, which tack­les car­diopul­monary dis­eases, un­til around Jan­u­ary 2018.

→ Hop­ing to up its game in T cell en­gi­neer­ing and man­u­fac­tur­ing, CAR-T con­tender Juno has ap­point­ed Ann Lee as EVP of tech­ni­cal op­er­a­tions and Patrick Yang as EVP, se­nior ad­vi­sor to the CEO. Yang was the in­ter­im leader of tech­ni­cal op­er­a­tions be­fore Lee came on board. Both have spent time at Roche/Genen­tech and Mer­ck & Co, and their ex­per­tise will like­ly be key as Juno looks to make a come­back and strides to­wards com­mer­cial­iza­tion.

Chris­t­ian Wey­er

→ Liv­er dis­ease play­er In­ter­cept Phar­ma­ceu­ti­cals $ICPT has ap­point­ed Chris­t­ian Wey­er as EVP of re­search and de­vel­op­ment. “Build­ing on a strong sci­en­tif­ic foun­da­tion with com­pelling clin­i­cal ev­i­dence, In­ter­cept is lead­ing the in­dus­try’s most ad­vanced clin­i­cal de­vel­op­ment pro­gram in NASH, a preva­lent and se­ri­ous dis­or­der with glob­al health-eco­nom­ic im­pact and no cur­rent­ly avail­able phar­ma­co­log­i­cal treat­ment op­tions,” Wey­er said in a state­ment. In case you’re won­der­ing, David Shapiro, who used to jug­gle that job with chief med­ical of­fi­cer du­ties, will con­tin­ue serv­ing as CMO.

→ Af­ter pre­sent­ing stel­lar da­ta on NK­TR-214 at SITC, Nek­tar Ther­a­peu­tics $NK­TR has el­e­vat­ed some of the staffers in­volved in the pro­gram to se­nior po­si­tions. Stephen Dober­stein, for­mer­ly head of the dis­cov­ery team, is now chief re­search & de­vel­op­ment of­fi­cer and SVP of R&D; Mary Tagli­a­fer­ri, who of­fered strate­gic lead­er­ship as VP of clin­i­cal de­vel­op­ment, is be­ing pro­mot­ed to chief med­ical of­fi­cer and SVP of clin­i­cal de­vel­op­ment; Jonathan Za­levsky is now chief sci­en­tif­ic of­fi­cer and SVP of re­search. As VP of bi­ol­o­gy and pre­clin­i­cal de­vel­op­ment, Za­levsky ad­vanced NK­TR-262, a small mol­e­cule TLR ag­o­nist be­ing de­vel­oped in com­bi­na­tion with NK­TR-214.

Herb Cross is serv­ing as Ar­mo Bio­sciences’ first chief fi­nan­cial of­fi­cer fol­low­ing stints at Bal­ance Ther­a­peu­tics and Kalo­Bios Phar­ma­ceu­ti­cals. Mean­while, the im­muno-on­col­o­gy com­pa­ny’s CEO, Pe­ter Van Vlas­se­laer, has been named chair­man of the board at Dutch bio­phar­ma TM3 Ther­a­peu­tics.

Acte­lion co-founder Thomas Wid­mann has been ap­point­ed to the board of Can­cer Ge­net­ics In­cor­po­rat­ed $CGIX, a di­ag­nos­tic and dis­cov­ery ser­vice provider fo­cused on pre­ci­sion med­i­cine.

Shire’s Flem­ming Orn­skov has re­cruit­ed An­dreas Busch as his new R&D chief and chief sci­en­tif­ic of­fi­cer, hand­ing him the reins for the pipeline as the CEO com­pletes a mis­sion to re­make Shire in­to a rare dis­ease spe­cial­ist. That comes im­me­di­ate­ly af­ter Bay­er an­nounced that Busch, the for­mer head of dis­cov­ery, is leav­ing as the phar­ma melds its ear­ly re­search and de­vel­op­ment op­er­a­tions un­der one of­fice oc­cu­pied by cur­rent de­vel­op­ment chief Jo­erg Moeller. Al­so hap­pen­ing at Shire $SH­PGThomas Dit­trich has been tapped to re­place cur­rent CFO Jeff Poul­ton, who is leav­ing at the end of this year. Where­as his most re­cent stint was at an in­dus­tri­al en­gi­neer­ing firm, Dit­trich had pre­vi­ous­ly worked in fi­nance roles at Am­gen for al­most a decade. 

Bio­gen has re­cruit­ed Jeff Capel­lo as CFO and ex­ec­u­tive vice pres­i­dent, fill­ing the po­si­tion a few months af­ter los­ing Paul Clan­cy to Alex­ion. Capel­lo, whose slate of pre­vi­ous em­ploy­ers spans Or­tho Clin­i­cal Di­ag­nos­tics, Boston Sci­en­tif­ic Cor­po­ra­tion and Perkin Elmer, jumps ship from Bea­con Health Op­tions, where he held the same roles. His fi­nan­cial ex­pe­ri­ence will like­ly be cru­cial for the big biotech {$BI­IB} as it ex­e­cutes a plan to “stream­line” op­er­a­tions.

→ A month ago George Scan­gos blazed through a biotech buy­out, two bil­lion-dol­lar drug de­vel­op­ment deals and more than $500 mil­lion in fi­nanc­ing to build a pipeline of new ther­a­pies for in­fec­tious dis­eases at his start­up biotech Vir. Now he’s se­lect­ed Her­bert “Skip” Vir­gin as R&D chief and CSO. Vir­gin is join­ing Vir from Wash­ing­ton Uni­ver­si­ty School of Med­i­cine in St. Louis, Mis­souri, where he has served as the Ed­ward Mallinck­rodt Pro­fes­sor and Chair of the De­part­ment of Pathol­o­gy & Im­munol­o­gy since 2006.

→ An­oth­er round of lead­er­ship changes is tak­ing place at In­trex­on {$XON}: re­tired lieu­tenant gen­er­al Thomas Bo­stick is slat­ed to re­place COO An­drew Last; Te­va vet Nir Nim­ro­di has been pro­mot­ed as chief busi­ness of­fi­cer; and He­len Sabze­vari is tak­ing the helm of Pre­ci­gen as pres­i­dent of the sub­sidiary. This marks the lat­est move by hands-on bil­lion­aire backer and CEO Ran­dal “RJ” Kirk, af­ter the high pro­file de­par­ture of then-pres­i­dent Gene Ger­mano in March. “A more stream­lined se­nior man­age­ment struc­ture is in line with our tran­si­tion to a group of re­lat­ed and in­creas­ing­ly com­mer­cial­ly ori­ent­ed en­ter­pris­es,” Kirk said in a state­ment.

→ Biotech vet­er­an Shao-Lee Lin will start at Hori­zon Phar­ma ear­ly next year as ex­ec­u­tive vice pres­i­dent, re­search and de­vel­op­ment and chief sci­en­tif­ic of­fi­cer. In this new po­si­tion, Lin joins CMO Jef­frey Sher­man in man­ag­ing the com­pa­ny’s grow­ing pipeline. As Hori­zon $HZNP gains a larg­er pres­ence in the or­phan drug field while and builds on its port­fo­lio of mar­ket­ed drugs, it could like use Lin’s ex­pe­ri­ence at Ab­b­Vie, Gilead and Am­gen lead­ing drug de­vel­op­ment across im­munol­o­gy, vi­rol­o­gy, in­flam­ma­tion and res­pi­ra­to­ry ther­a­peu­tics. Said Lin in a state­ment: “I’m im­pressed by Hori­zon’s rapid growth and its strat­e­gy for evo­lu­tion from pri­ma­ry care, with a fo­cus on mar­ket­ed med­i­cines, to di­ver­si­fy­ing in­to rare dis­eases and rheuma­tol­ogy and now com­mit­ted to the next stage in its trans­for­ma­tion of build­ing a ro­bust and sus­tain­able re­search and de­vel­op­ment port­fo­lio.”

→ Pere­grine Phar­ma­ceu­ti­cals re­cent­ly an­nounced it was scrap­ping its old busi­ness and tran­si­tion­ing in­to a con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO). The com­pa­ny is al­so toss­ing the Pere­grine name, and do­ing busi­ness in­stead as Avid Bioser­vices (a for­mer “side busi­ness” of Pere­grine that now em­ploys most of its peo­ple and earns the ma­jor­i­ty of its rev­enue). As part of that re­or­ga­ni­za­tion, Roger Lias was brought on to lead Avid as pres­i­dent of the com­pa­ny. Lias was pre­vi­ous­ly at Al­ler­gan, where he worked as head of glob­al bi­o­log­ics busi­ness de­vel­op­ment.

→ CRO Bio­Clin­i­ca has named David Her­ron as the com­pa­ny’s in­com­ing CEO, ef­fec­tive Jan­u­ary 2, 2018. The ap­point­ment comes as Bio­Clin­i­ca’s cur­rent CEO John Hub­bard is re­tir­ing ear­ly next year. Hub­bard will stay on as a non-ex­ec­u­tive di­rec­tor on the CRO’s board. Her­ron has been at Bio­Clin­i­ca for the past 10 years, most re­cent­ly lead­ing the med­ical imag­ing busi­ness and its tech-fo­cused eHealth seg­ment.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

Momelotinib-focused Sierra Oncology, which launched a Phase III trial in November for myelofibrosis patients, has made Stephen Dilly its president and CEO, effective June 1. Dilly was previously the CEO at Aimmune from 2014 until what was billed as his retirement in 2018, but now he’s back at the helm of another company and is also a member of Sierra’s board of directors. Additionally, the seasoned vet has held posts at Genentech, Chiron and GSK.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

Ipsen has turned to another Paris-based biopharma company for its next CEO.

Sanofi Pasteur chief David Loew — who’s been leading one of the most advanced efforts to develop vaccines for Covid-19 — is making the journey to Ipsen, 5 months after David Meek jumped ship to run a startup in late-stage development.

Loew arrives as Ipsen works to get back on track with their rare bone disease drug palovarotene, picked up in the $1.3 billion Clementia buyout, which was slammed with a partial hold after researchers observed cases of “early growth plate closure” in patients under the age of 14. But they are pushing ahead with the over-14 crowd after writing down slightly more than half of its initial development.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.